PORTFOLIO
PORTFOLIO COMPANIES
COMPANY PROFILE
Improving drug properties through chemical generation of glycosylated peptides and proteins
GlyTech is a pioneer in glycoscience/glycotechnology. GlyTech has established the world’s first large-scale manufacturing process for highly purified and characterized human-type N-glycans as well as technology for the chemical synthesis of high-purity glycopeptides, glycoproteins, and other glycosylated compounds.
GlyTech’s technologies are expected to contribute to the development of safer and more cost-effective biopharmaceuticals. GlyTech aims to play a significant role in the creation of innovative biobetters with high functionality.
GlyTech’s technologies are expected to contribute to the development of safer and more cost-effective biopharmaceuticals. GlyTech aims to play a significant role in the creation of innovative biobetters with high functionality.
COMPANY STORY
Origin
Glytech was incorporated with the goals of realizing the practical mass production of highly pure glycans and demonstrating the capabilities of glycans to functionalize biomedical products in 2012. These technologies are based on the research results of the founder's previous work at Otsuka Chemical Co., Ltd. and a collaborative research project with Professor Yasuhiro Kajihara of Osaka University.
Strength
Drug discovery screening system and commercial production of drug substance through precise and rapid chemical synthesis of biopharmaceutical drugs and compounds such as glycopeptides and glycoproteins.
UTEC’s value add
UTEC has provided assistance with financing and governance structuring after Series A round and beyond.
-
Attachment of Glycans to Peptides/Proteins via Solid or Solution Phase Synthesis
-
Laboratory
